Semantic Laboratories
Solutions for Drug Discovery Research Intelligence

Carlos S. Zamudio

Carlos S. Zamudio has over 20 years of experience leading teams in the development of informatics solutions and laboratory technologies for the biotechnology industry. He has led the integration and development of Corporate and Research IT solutions as well as the establishment of drug discovery informatics platforms for bioinformatics, cheminformatics and pharmacoinformatics research. Carlos S. Zamudio's experience in the life sciences and biotechnology industry includes the following leadership positions:

Vice President of Drug Discovery Informatics at Elitra Pharmaceuticals, a drug discovery company focused on the development of novel antimicrobial therapeutics

Vice President of Bioinformatics at Axiom Biotechnologies, a platform company focused on the development of novel high-throughput cell pharmacology instrumentation and cell-lines

Director of Bioinformatics and Engineering at Sequana Therapeutics, a genomics company focused on the discovery of novel disease targets using population genetics, positional cloning and genome sequencing methods

Group Leader at Applied Biosystems, pioneered the commercial development of ABI's software products to integrate DNA and protein instrumentation and analysis

Product Development Manager at TRW Information Systems Group, applying TRW advanced technologies to the Financial Services industry and the Life Sciences through a collaboration with Caltech

Carlos has actively participated in a number of Joint Review Committees (JRC) within drug discovery and technology development collaborations with pharmaceutical companies, including Merck, Kaken, LG Chem, Incyte Pharmaceutics and Celera Genomics.  He was also elected as a member of the Board of Scientific Counselors for the National Center for Biotechnology Informatics (NCBI) within the National Library of Medicine.

He is currently focused on the integration and development of data semantic solutions throughout the drug discovery process, to create re-usable drug discovery knowledge and unleash the full potential of the new experimental platforms used throughout discovery research.

Recent Publications

Wang L, Trawick JD, Yamamoto R, Zamudio C (2004) Genome-wide operon prediction in Staphylococcus aureus.  Nucleic Acids Res. 2004 Jul 13; 32(12):3689-702

Forsyth RA, Haselbeck RJ, Ohlsen KL, Yamamoto RT, Xu H, Trawick J, Wall D, Wang L, Brown-Driver V, Foelich JM, C KG, King P, McCarthy L, Malone C, Misiner B, Robbins D, Tan Z, Zhu Z, Carr G, Mosca DA, Zamudio C, Foulkes JG, Zyskind JW (2002) A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 2002 Mar; 43(6): 1387-400

Recent Training

• Biostatistics, UCSD (2003)

• Medicinal Chemistry, UCSD Extension (2004)

• Pharmacokinetics, UCSD Extension (2005)

• Analytical Chemistry, UCSD Extension (2005)

Intellectual Property

U.S. Patent Application Serial No. 10/072,851 (see International PCT patent application Publication No. WO 02/086097).  Methods for Identifying the Target of an Antimicrobial Drug

U.S. Patent Application Publication No. 200300111013.   Identification Of Essential Genes of Aspergillus fumigatus and Methods of Use

U.S. Patent Application Publication No. 20040029129.  Genes Identified as Essential for Proliferation in Prokaryotes

U.S. Patent Application Publication No. 20040014955.  Identification Of Essential Genes of Cryptococcus neoformans and Methods of Use

U.S. Provisional Application No. 60/474,768.  Microbial Operons

Additional Info:

• Carlos S. Zamudio's web log (blog)

• Recommended reading list

• Send email to Carlos S. Zamudio